PE20150902A1 - Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociado - Google Patents

Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociado

Info

Publication number
PE20150902A1
PE20150902A1 PE2015000501A PE2015000501A PE20150902A1 PE 20150902 A1 PE20150902 A1 PE 20150902A1 PE 2015000501 A PE2015000501 A PE 2015000501A PE 2015000501 A PE2015000501 A PE 2015000501A PE 20150902 A1 PE20150902 A1 PE 20150902A1
Authority
PE
Peru
Prior art keywords
treatment
diabetes
heterociclil
tetrahidro
piran
Prior art date
Application number
PE2015000501A
Other languages
English (en)
Inventor
Ranjit C Desai
Rajesh Bahekar
Pradip Jadav
Amitgiri Goswami
Pankaj Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of PE20150902A1 publication Critical patent/PE20150902A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invencion se relaciona con compuestos de la formula general (I) sus formas tautomericas, sus enatiomeros, sus diastereomeros, sus sales farmaceuticamente aceptadas, o pro-farmacos de los mismos, que son utiles para el tratamiento o prevencion de diabetes mellitus (DM), obesidad y otros trastornos metabolicos. La invencion tambien se relaciona con el proceso para la fabricacion de dichos compuestos, y composiciones farmaceuticas que los contienen y su uso. Los compuestos preferidos son: (2R, 3S, 5R)-2-(2,5-difluorofenil)-5-(5-(metilsulfonil)-hexahidro-pirrolo [3,4-c]pirrol-2 (1H)-il) tetrahidro-2H-piran-3 amina; (2R S,5R)-2-(2,5-difluorofenil)-5-(7-(metilsulfonil)-2,7-diazaspiro [4. 4]-nonan-2-il) tetrahidro-2H-piran-3-anima, entre otros
PE2015000501A 2012-10-17 2013-10-17 Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociado PE20150902A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3030MU2012 2012-10-17

Publications (1)

Publication Number Publication Date
PE20150902A1 true PE20150902A1 (es) 2015-06-25

Family

ID=49917687

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000501A PE20150902A1 (es) 2012-10-17 2013-10-17 Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociado

Country Status (23)

Country Link
US (1) US20150246025A1 (es)
EP (1) EP2909199A1 (es)
JP (1) JP2016500685A (es)
KR (1) KR20150070325A (es)
CN (1) CN104736534A (es)
AP (1) AP2015008366A0 (es)
AR (1) AR093047A1 (es)
AU (1) AU2013333405A1 (es)
BR (1) BR112015008717A2 (es)
CA (1) CA2886710A1 (es)
CL (1) CL2015000976A1 (es)
CO (1) CO7350641A2 (es)
EA (1) EA201590735A1 (es)
HK (1) HK1207860A1 (es)
IL (1) IL238027A0 (es)
MA (1) MA38079A1 (es)
MX (1) MX2015004846A (es)
PE (1) PE20150902A1 (es)
PH (1) PH12015500860A1 (es)
SG (1) SG11201502653VA (es)
TW (1) TWI500613B (es)
WO (1) WO2014061031A1 (es)
ZA (1) ZA201502290B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085528A (zh) * 2014-05-15 2015-11-25 成都贝斯凯瑞生物科技有限公司 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物
WO2016014324A1 (en) * 2014-07-21 2016-01-28 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-iv inhibitors
CN106478631B (zh) * 2015-08-24 2019-04-05 四川科伦药物研究院有限公司 长效二肽基肽酶-iv抑制剂、用途及其中间体的制备方法
TWI682933B (zh) * 2015-08-27 2020-01-21 大陸商四川海思科製藥有限公司 三員稠合環取代的胺基六員環類衍生物及其在醫藥上的應用
CN105198847B (zh) * 2015-10-28 2017-05-17 四川凯科医药科技有限公司 一种化合物的制备方法
CN106146405B (zh) * 2016-06-22 2018-11-30 湖北生物医药产业技术研究院有限公司 药物杂质中间体及其制备方法和用途
RS59306B1 (sr) * 2017-03-20 2019-10-31 Forma Therapeutics Inc Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr)
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
US12122778B2 (en) 2018-09-19 2024-10-22 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN109928971B (zh) * 2019-03-14 2024-01-16 广东东阳光药业股份有限公司 芳基取代的氨基四氢吡喃类化合物及其用途
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN115304605B (zh) * 2022-01-21 2023-10-03 陕西国际商贸学院 具有抗肿瘤活性的氧杂环丁烷衍生物及其制备方法和应用
WO2024112764A1 (en) 2022-11-21 2024-05-30 Novo Nordisk Health Care Ag Synthesis of pyrrolo[3,4-c]pyrroles

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6617340B1 (en) 1999-07-29 2003-09-09 Novartis Ag N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DE19942305C2 (de) 1999-09-04 2001-06-28 Solvay Fluor & Derivate Herstellung hochreiner Fluorverbindungen
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6432969B1 (en) 2000-06-13 2002-08-13 Novartis Ag N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU2002306823B2 (en) 2001-03-27 2006-05-11 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
ES2257555T3 (es) 2001-06-20 2006-08-01 MERCK & CO., INC. Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes.
DE60224189T2 (de) 2001-06-20 2008-12-11 Merck & Co., Inc. Dipeptidylpeptidase-hemmer zur behandlung von diabetes
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
CN100341862C (zh) 2001-09-14 2007-10-10 三菱制药株式会社 噻唑烷衍生物及其医药用途
GB0125446D0 (en) 2001-10-23 2001-12-12 Ferring Bv Novel anti-diabetic agents
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
ATE373660T1 (de) 2002-03-25 2007-10-15 Merck & Co Inc Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
CA2490818A1 (en) 2002-07-15 2004-01-22 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
DE10238470A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
EP1560811B9 (en) 2002-09-19 2008-03-05 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
ES2291680T3 (es) 2002-10-07 2008-03-01 MERCK & CO., INC. Antidiabeticos beta-amino heterociclicos inhibidores de la dipeptidil peptidasa.
WO2004037181A2 (en) 2002-10-23 2004-05-06 Bristol-Myers Squibb Company Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
WO2004041795A1 (en) 2002-10-30 2004-05-21 Guilford Pharmaceuticals Inc. Novel inhibitors of dipeptidyl peptidase iv
PL376822A1 (pl) 2002-11-07 2006-01-09 Merck & Co., Inc. Pochodne fenyloalaniny jako inhibitory dipeptydylopeptydazy do leczenia lub zapobiegania cukrzycy
BR0316327A (pt) 2002-11-18 2005-09-27 Pfizer Prod Inc Amidas cìclicas fluorinadas inibidoras de dipeptidilpeptidase iv
EP1578414A4 (en) 2002-12-04 2007-10-24 Merck & Co Inc PHENYLALANINE DERIVATIVES ALSDIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
JP4504924B2 (ja) 2002-12-20 2010-07-14 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
WO2004064778A2 (en) 2003-01-17 2004-08-05 Merck & Co. Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2006516573A (ja) 2003-01-31 2006-07-06 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
WO2004071454A2 (en) 2003-02-13 2004-08-26 Guilford Pharmaceuticals Inc. Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv
EP1761532B1 (en) 2004-06-21 2013-04-10 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
DE102004038270A1 (de) * 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Amino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP4797021B2 (ja) 2004-10-01 2011-10-19 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療または予防用のジペプチジルペプチダ−ゼ−ｉｖ阻害剤としてのアミノピペリジン
EP1888066B1 (en) * 2005-05-25 2012-01-11 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
ATE549926T1 (de) 2005-08-26 2012-04-15 Merck Sharp & Dohme Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
AU2007208405B2 (en) * 2006-01-25 2011-05-26 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US7910596B2 (en) * 2006-02-15 2011-03-22 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
CN101410400B (zh) * 2006-03-28 2012-09-05 默沙东公司 作为用于糖尿病治疗或者预防的二肽基肽酶-ⅳ抑制剂的氨基四氢吡喃
TW200806669A (en) 2006-03-28 2008-02-01 Merck & Co Inc Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2007136603A2 (en) * 2006-05-16 2007-11-29 Merck & Co., Inc. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7855206B2 (en) 2006-11-14 2010-12-21 Merck Sharp & Dohme Corp. Tricyclic heteroaromatic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2009025784A1 (en) * 2007-08-21 2009-02-26 Merck & Co., Inc. Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CN101468988A (zh) 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
MX2010012245A (es) 2008-05-14 2011-04-11 Sanwa Kagaku Kenkyusho Co Medicina que consiste del uso concomitante o combinacion de un inhibidor de dpp-iv y otra medicina para diabeticos.
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
CN101619064B (zh) 2008-07-01 2011-05-11 韶远化学科技（上海）有限公司 多氮杂环医药中间体的合成及工艺方法
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
US20120010186A1 (en) * 2009-03-23 2012-01-12 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US8455533B2 (en) * 2009-09-02 2013-06-04 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US8716482B2 (en) * 2009-09-25 2014-05-06 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
US8853212B2 (en) 2010-02-22 2014-10-07 Merck Sharp & Dohme Corp Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
CN102260265B (zh) * 2010-05-24 2015-09-02 上海阳帆医药科技有限公司 六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途
WO2012101654A2 (en) 2011-01-25 2012-08-02 Sphaera Pharma Pvt. Ltd Novel triazine compounds
US8907086B2 (en) 2011-03-03 2014-12-09 Merck Sharp & Dohme Corp. Fused bicyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
AU2012275638A1 (en) 2011-06-29 2013-11-14 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitors
US9073930B2 (en) 2012-02-17 2015-07-07 Merck Sharp & Dohme Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

Also Published As

Publication number Publication date
BR112015008717A2 (pt) 2017-07-04
SG11201502653VA (en) 2015-05-28
WO2014061031A1 (en) 2014-04-24
US20150246025A1 (en) 2015-09-03
AP2015008366A0 (en) 2015-04-30
EA201590735A1 (ru) 2016-04-29
CN104736534A (zh) 2015-06-24
CO7350641A2 (es) 2015-08-10
TW201429960A (zh) 2014-08-01
EP2909199A1 (en) 2015-08-26
AU2013333405A1 (en) 2015-05-07
MX2015004846A (es) 2015-07-21
KR20150070325A (ko) 2015-06-24
JP2016500685A (ja) 2016-01-14
MA38079A1 (fr) 2016-09-30
CA2886710A1 (en) 2014-04-24
CL2015000976A1 (es) 2015-12-18
AR093047A1 (es) 2015-05-13
PH12015500860A1 (en) 2015-06-22
HK1207860A1 (en) 2016-02-12
ZA201502290B (en) 2016-01-27
TWI500613B (zh) 2015-09-21
IL238027A0 (en) 2015-05-31

Similar Documents

Publication Publication Date Title
PE20150902A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociado
AR089554A1 (es) Formas cristalinas de un inhibidor de la dipeptidil peptidasa-iv
MX2009013830A (es) Compuestos antivirales.
UA98494C2 (uk) Противірусні сполуки
EA201891099A1 (ru) 7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
CL2012002487A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina, inhibidores de pde10; composicion farmacéutica que los comprende; proceso para preparar la composicion farmaceutica; utiles para el tratamiento de enfermedades neurológicas, psiquiátricas o metabólicas tales como esquizofrenia, parkinson y diabetes, entre otras.
CL2012000795A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak); composicion farmaceutica que comprnde a uno de dichos compuestos; y su uso para la preparacion de medicamentos utiles en el tratamiento de alzheimer, cancer, artritis, leucemia, diabetes, enfermedades inflamatorias y autoinmunes, entre otras.
CL2008001612A1 (es) 5-(3-hidroxi-7-sustituido-naftalen-2-il)-1, 1-dioxo-[1,2,5]tiadiazolidin-3-ona; su uso para tratar un trastorno hiperproliferativo; la composicion farmaceutica que los contiene; y sus procesos de preparacion.
CL2008001709A1 (es) Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
WO2012068234A3 (en) Antiviral compounds
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
CL2011001094A1 (es) Compuesto derivados de pirazin-2-iloxi, inhibidores de pde10; composición farmacéutica que comprende a los compuestos; y uso de los compuestos en la preparación de medicamentos para tratar enfermedades, tales como obesidad, diabetes no dependiente de insulina, esquizofernia, bipolaridad, trastorno obsesivo-compulsivo y similares.
MX2019003738A (es) Compuestos antivirales.
TW200614996A (en) Antiviral compounds
UA91688C2 (en) Antiviral compounds
WO2009005690A3 (en) Antiviral compounds
UY30282A1 (es) Compuestos quimicos
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
MX2010009646A (es) Agentes terapeuticos antivirales.
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
PH12018500377A1 (en) Novel annelated benzamides
PH12018500378A1 (en) Novel annelated phenoxyacetamides
MX2022005915A (es) Tratamiento de eccema de las manos.

Legal Events

Date Code Title Description
FD Application declared void or lapsed